JPRN-jRCT2080220027未知3 期
CS-866DM phase 3 comparative study (ORIENT)
DAIICHISANKYO Co.,Ltd.0 个研究点开始时间: 2005年9月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 30age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •-Patient, age 30-70.
- •-Albumin-to-creatinine ratio >=300 mg/g-creatinine in first morning urinalysis
- •-Serum creatinine between 1.0 and 2.5 mg/dL in women and between 1.2 and 2.5 mg/dL in men
排除标准
- •-History of cerebrovascular or cardiovascular disease
- •-Rapid progression of kidney disease within 3 months
- •-Patient with extremely poor glycemic control
研究者
相似试验
未知
3 期
CS-801 phase 3 comparative studyOveractive bladderJPRN-jRCT2080220025Sankyo Co.,Ltd.
进行中（未招募）
1 期
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple MyelomaCTIS2023-506588-32-00Janssen - Cilag International397
进行中（未招募）
1 期
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple MyelomaRelapsed and lenalidomide-refractory multiple myeloma (MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2019-001413-16-BEJanssen-Cilag International NV400
进行中（未招募）
1 期
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple MyelomaRelapsed and lenalidomide-refractory multiple myeloma (MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2019-001413-16-ITJANSSEN CILAG INTERNATIONAL NV400
进行中（未招募）
1 期
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple MyelomaEUCTR2019-001413-16-GBJanssen-Cilag International NV400